A Locke Lord team led by Keith Parr (Chicago) represented Lupin Atlantis Holdings, S.A., Lupin Pharmaceuticals Inc., and Lupin Ltd. in defending against a motion for a temporary restraining order filed by Taro Pharmaceuticals U.S.A., Inc. and Taro Pharmaceuticals North America, Inc. following Lupin’s launch of its desoximetasone topical spray (0.25 percent) product. Taro asserted in its motion for a temporary restraining order that Lupin’s generic product would infringe two Taro patents that were listed in the FDA’s Orange Book for Taro’s TOPICORT® product. The U.S. District Court for the District of New Jersey denied Taro’s motion finding that Taro had not proven a substantial likelihood of success on the merits or that it would be irreparably harmed by Lupin’s launch. After Taro’s motion was denied, Taro decided not to proceed with a motion for a preliminary injunction. The Locke Lord team included David Abramowitz, Tim Peterson and Nina Vachhani (all of Chicago).
Posted on August 10, 2018